RY1 Inhibitors
Chemical inhibitors of RY1 can impede its function through various mechanisms related to the protein's role in RNA processing. Alsterpaullone, by inhibiting cyclin-dependent kinases (CDKs) like CDK1 and CDK2, can disrupt the cell cycle, which is closely tied to the RNA processing events in which RY1 is involved. The inhibition of CDKs could lead to an unfavorable environment for the proper function of RY1 in spliceosome-mediated RNA processing. Similarly, roscovitine selectively targets CDKs, which may lead to reduced phosphorylation of proteins that are crucial for RNA splicing, indirectly constraining RY1 activity. Flavopiridol, another CDK inhibitor, can interrupt transcriptional elongation, potentially altering the pre-mRNA processing landscape, thereby indirectly impeding RY1's role in these pathways.
Further indirect inhibition of RY1 is seen with Indirubin-3'-monoxime, which inhibits both CDKs and GSK-3β, a kinase implicated in numerous cellular processes including RNA processing. This inhibition can create a cellular milieu that is less conducive for RY1's normal functioning. The adenosine kinase inhibitor 5-Iodotubercidin raises intracellular adenosine levels, which can interfere with ATP-dependent RNA helicases, thereby affecting RY1's RNA metabolism activities. Olomoucine, similar to other CDK inhibitors mentioned, can modify the phosphorylation state of proteins involved in mRNA splicing, with potential indirect repercussions on RY1 activity. DRB targets RNA polymerase II, essential for mRNA synthesis, and its inhibition could reduce the substrate availability for RY1 function in RNA processing. The protein kinase A inhibitor H-89 dihydrochloride, phosphoinositide 3-kinase inhibitors wortmannin and LY294002, and the mTOR inhibitor rapamycin all disrupt various signaling pathways that indirectly influence the RNA processing activities of RY1. Lastly, U0126 impedes MEK1/2, affecting the MAPK signaling pathway, which has regulatory roles in RNA processing that are crucial for RY1's activity. Each of these chemicals, through their distinct actions on cellular signaling and enzymatic pathways, can create conditions that are unfavorable for RY1's function in RNA processing, leading to its inhibition.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Alsterpaullone | 237430-03-4 | sc-202453 sc-202453A | 1 mg 5 mg | $68.00 $312.00 | 2 | |
Alsterpaullone inhibits cyclin-dependent kinases such as CDK1 and CDK2. As RY1 is involved in RNA processing, CDK inhibition can disrupt the cell cycle and thus indirectly inhibit the processing of RNA, a function in which RY1 is implicated. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $94.00 $265.00 | 42 | |
Roscovitine selectively inhibits CDKs, which may impede the phosphorylation of proteins involved in RNA splicing, thereby indirectly inhibiting RY1 function in spliceosome-mediated RNA processing. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $259.00 | 41 | |
Flavopiridol is a CDK inhibitor that can disrupt transcriptional elongation. By inhibiting transcriptional elongation, it may indirectly inhibit RY1's role in the processing of pre-mRNA transcripts. | ||||||
Indirubin-3′-monoxime | 160807-49-8 | sc-202660 sc-202660A sc-202660B | 1 mg 5 mg 50 mg | $79.00 $321.00 $671.00 | 1 | |
This compound is known to inhibit CDKs and glycogen synthase kinase 3 beta (GSK-3β). By inhibiting GSK-3β, which is involved in a plethora of cellular functions including RNA processing, RY1's function could be indirectly inhibited due to disruption of these processes. | ||||||
5-Iodotubercidin | 24386-93-4 | sc-3531 sc-3531A | 1 mg 5 mg | $153.00 $464.00 | 20 | |
As an adenosine kinase inhibitor, 5-Iodotubercidin increases intracellular adenosine levels, which can disrupt ATP-dependent RNA helicases, possibly affecting RY1's function in RNA metabolism. | ||||||
Olomoucine | 101622-51-9 | sc-3509 sc-3509A | 5 mg 25 mg | $72.00 $274.00 | 12 | |
Another CDK inhibitor, olomoucine, may indirectly inhibit RY1 by altering the phosphorylation state of proteins involved in mRNA splicing and processing. | ||||||
DRB | 53-85-0 | sc-200581 sc-200581A sc-200581B sc-200581C | 10 mg 50 mg 100 mg 250 mg | $43.00 $189.00 $316.00 $663.00 | 6 | |
DRB inhibits RNA polymerase II, which is essential for the synthesis of mRNA. As RY1 is involved in RNA processing, inhibiting synthesis can indirectly inhibit its function. | ||||||
H-89 dihydrochloride | 130964-39-5 | sc-3537 sc-3537A | 1 mg 10 mg | $94.00 $186.00 | 71 | |
H-89 is a protein kinase A inhibitor, which can influence RNA processing pathways and thereby indirectly inhibit RY1. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent inhibitor of phosphoinositide 3-kinases, which are involved in signaling pathways that may indirectly influence the RNA processing in which RY1 participates. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is another inhibitor of phosphoinositide 3-kinases, potentially disrupting signaling pathways that indirectly modulate RNA processing functions of RY1. | ||||||